{
  "docId": "019de074-7a94-707c-b002-278357aaec02",
  "docSlug": "fb2ab974265a0e95c40d5a8a75128cd1",
  "documentTitle": "BenevolentAI | Results Presentation Deck | 38 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 38,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide contrasts the market size and unmet needs of UC with the specific mechanism and target patient population for BEN-8744.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7a94-707c-b002-278357aaec02/19",
  "deckHref": "/decks/019de074-7a94-707c-b002-278357aaec02",
  "deckJsonHref": "/decks/019de074-7a94-707c-b002-278357aaec02.json",
  "deckAnchorHref": "/decks/019de074-7a94-707c-b002-278357aaec02#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.48,
        "x": 0.48,
        "y": 0.06
      },
      "kind": "callout",
      "text": "BEN-8744: Oral, peripherally-restricted, PDE10 inhibitor under development as a first-in-class treatment for refractory UC",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66db6497-1f15-432a-8180-8c535c96c66f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "A chronic, lifelong disease that causes inflammation and ulceration of the inner lining of the colon and rectum. 64% of patients are mild-moderate, 31% are moderate-severe, 5% are severe-fulminant. Efficacy/Safety gaps in current treatments.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8f204a4-9748-4a9a-95ac-a7520889cba2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.45,
        "y": 0.28
      },
      "kind": "list",
      "text": "Phosphodiesterase 10 (PDE10) identified as novel target. BEN-8744 designed as best-in-class oral inhibitor. Targets moderate/severe patients, addressing unmet needs in refractory cohorts with improved safety.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "faf1ee50-74ba-4ffa-834e-5d85d12299a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.38,
        "x": 0.05,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "Affects 0.4% US population(1), 1.7 million patients in 7MM(1), forecast $7.8bn market by 2026(2)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6896ea98-41cf-4a6a-922e-16ed9d4032fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.01,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Sources: (1) GlobalData; (2) Evaluate Pharma; (3) Roda et al.; (4) Kobayashi et al.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cef7a583-7f74-40d5-9c22-c9a8bf656a5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "BEN-8744 Ulcerative Colitis (UC)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3508fae6-ff07-4084-ac68-e58597b62147",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 19,
      "beatId": "0b3305fb-04d7-41a4-9e31-d70cab163020",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The section on BEN-8744 Ulcerative Colitis (UC) presents a clear problem statement.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 19,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a12bae4b-f3d9-48f0-b149-d669300e0f3c",
      "evidence": "The section on BEN-8744 Ulcerative Colitis (UC) implies the cost of inaction.",
      "position": 0,
      "objective": "What is the cost of not addressing Ulcerative Colitis?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}